SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
Bria-IMT Cancer Vaccine Shows Efficacy, Tolerability in Advanced Breast Cancer
A phase 1/2 study showed that treatment with cyclophosphamide, SV-BR-1-GM, and retifanlimab yields favorable survival data in heavily pretreated patients with breast cancer.
LumiSystem in Lumpectomy May Reduce or Omit Radiation in Breast Cancer
Broader margins used in lumpectomies can lead to a reduced radiation target area in patients with breast cancer, according to results from a study presented at the 2024 SABCS.
Ivonescimab/Chemo Combo Yields Positive Efficacy and Safety Results in TNBC
Ivonescimab with chemotherapy elicited a median progression-free survival of 9.36 months in patients with locally advanced unresectable or metastatic triple-negative breast cancer.
Zanidatamab/Evorpacept Combo Yields Promising Activity in HER2+ Breast Cancer
Phase 1b/2 data show antitumor activity with zanidatamab/evorpacept, including among heavily pretreated patients with HER2-low metastatic breast cancer.
Tislelizumab Triplet Shows Meaningful Responses, PFS in Metastatic TNBC
Phase 2 data indicate that CD8 status may serve as a biomarker for predicting treatment efficacy with tislelizumab-based treatment in TNBC.
Tirzepatide May Increase AEs in HR+/HER2– Breast Cancer Treatment
The FITWISE clinical trial assessed the safety and tolerability of breast cancer treatments when patients use tirzepatide.
SHR-A1811 Shows Promising Activity in HR+/HER2-Low Breast Cancer
The first stage of a phase 2 trial evaluating neoadjuvant SHR-A1811 in breast cancer meets its primary end point of ORR.
Additional Excision of Margin Tissue Did Not Alter Satisfaction in Breast Cancer
LumiSystem prompted the removal of a median of 10.5cc extra tumor margin tissue in patients with breast cancer and did not significantly affect satisfaction outcomes.
PM8002/BNT327 Combo Improves Efficacy and Safety in Metastatic TNBC
Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.
Bolstering Access to Breast Cancer Screening for Genome Markers
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC
The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.
Top 10 Findings Shaping the Future of Breast Cancer Care From SABCS 2024
SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.
Elacestrant Combos Can Open New Pathways in ESR1 Breast Cancer Treatment
Multiple targeted therapies/sequencing possibilities are available following elacestrant’s approval for patients with breast cancer, Maxwell Lloyd, MD, said.
Elacestrant’s Real World Outcomes Improve Over Clinical Findings in Breast Cancer
Since elacestrant’s emergence in the real-world setting, it has demonstrated superior efficacy outcomes compared with what the EMERALD study found.
Elacestrant With Targeted Agents May Overcome ET Resistance in Breast Cancer
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Camizestrant/Ribociclib Improves PFS and Responses in ER+/HER2– Breast Cancer
Patients with ER+/HER2– advanced breast cancer saw positive efficacy and safety data following treatment from the SERENA-1 trial.
Elacestrant Plus CDK4/6i May Optimize ESR1+ Breast Cancer Outcomes
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
ctDNA at Baseline Linked With Larger Tumor Size and Residual Cancer Burden
Ultra-sensitive ctDNA testing identified ctDNA at baseline in patients with HR–positive breast cancer, results from the PELOPS trial showed.
Health-Related Quality of Life Complimented Efficacy/Safety With T-DXd in Breast Cancer
Atezolizumab with Neoadjuvant Chemo Does Not Meet End Points in TNBC
Atezolizumab with chemotherapy did not yield a significant increase to event-free survival compared with placebo with chemotherapy, 85.2% vs 81.9%, respectively.
Niraparib/Dostarlimab Shows Promise in BRCA+ ER+/HER2– Breast Cancer
Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.
Response Rates Were Improved for Camrelizumab/Chemo vs Chemo in TNBC
The phase 3 CamRelief study reported a pathologic complete response rate of 56.8% for camrelizumab plus chemo compared with 44.7% for chemo alone.
Ribociclib and Endocrine Therapy Show Favorable PFS Trend in Breast Cancer
Data from the RIGHT Choice study showed that ribociclib/ET yielded efficacy benefits for luminal B/HER2E breast cancer vs combination chemotherapy.
Palbociclib/ET/anti-HER2 Therapy Demonstrates Clinical Benefit in Breast Cancer
Palbociclib combination therapy elicited a progression-free survival of 44.3 months compared with the 29.1 months of SOC in HR+, HER2+ breast cancer.
Imlunestrant Sees Improved Efficacy vs SOC in ESR1+ Advanced Breast Cancer
Data from the EMBER-3 trial showed improved progression-free survival with imlunestrant with or without abemaciclib vs SOC in ER+/HER2– breast cancer.
Elacestrant/Abemaciclib Produces Clinical Benefit in Metastatic Breast Cancer
Elascestrant with abemaciclib elicited an overall response rate of 18% in ER+/HER2– Breast Cancer, results from the 2 trials show.
Exclusive Radiation Therapy Improves QOL and Safety Outcomes in Breast Cancer
When compared with endocrine therapy, radiation therapy improved quality of life and adverse effects data, the phase 3 EUROPA study showed.
Tamoxifen Shows Significant Reduction in Overall Recurrence in Breast Cancer
Analysis of NRG/RTOG 9804 and E5194 trials found tamoxifen significantly reduced invasive ipsilateral breast recurrence in patients with “good risk” DCIS treated without RT.
Active Monitoring Noninferior to Standard Surgery, RT in Low-risk DCIS
Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.